EMEA Member Resources
DIA members will enjoy complimentary access to the full text of the PLC Life Sciences multi-jurisdictional guides published by Practical Law.
Practical Law Company’s Life Sciences multi-jurisdictional provides practical information on topical issues and country-specific Q&A overviews on this area of law and practice. The guide features a comparative tool which allows the user to select a specific question or topic, select the jurisdictions they are interested in and the tool will compare the answers.The Q&A chapters are written by leading local law firms in each jurisdiction. The questions are designed by PLC’s team of ex-private practice lawyers alongside international editorial boards comprising of legal professionals (both in-house and private practice) active in that particular area. This helps to ensure the guides address the key issues facing any international lawyer doing business in an unfamiliar jurisdiction. If any member would like more information on a contributing law firm or has any feedback regarding the guides, please contact Yani.Paramova@practicallaw.com.
Physicians Need to Understand Drug Development…and a Lot More: Interview with DIA 2015 Co-Chair Dr. Michael Rosenblatt
“Many doctors who write a prescription may not have a sense of what’s behind that prescription in terms of discovery or development or regulatory oversight. We produce computer scientists and other experts in information technology but we wouldn’t dream of giving people degrees in those areas unless they understood the hardware and how the computer works. Well, we’re producing doctors year after year who really have no idea of how that pill got to them for them to prescribe it. It will benefit everyone – patients especially, and physicians – if there’s some understanding of the process, there may be opportunity for all to contribute to improving the process going forward.”
“Rare diseases really are the exemplar for what we now call precision medicine. We’re categorizing people’s illnesses not only on the basis of their symptoms but on the basis of some kind of biological variable, usually a genetic characterization. That’s what rare diseases have been doing for years. Scientists are now trying to ‘translate’ what they continue to learn about the genetic basis of rare diseases into a deeper understanding of the pathophysiology of common diseases, and they are making progress.”